Beraprost
Alternative Names: Befraprost; Dorner; ML 129; ML-1129; ML-1229; Procyclin; RU-55100; TRK-100Latest Information Update: 05 Nov 2023
At a glance
- Originator Toray
- Developer Kaken Pharmaceutical; sanofi-aventis; Toray; United Therapeutics Corporation
- Class 3-ring heterocyclic compounds; Alkynes; Antiplatelets; Benzofurans; Butyric acids; Cyclopentanes; Prostaglandins; Small molecules; Vasodilators
- Mechanism of Action Epoprostenol agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Arterial occlusive disorders; Peripheral vascular disorders; Pulmonary hypertension
- Discontinued Cancer; Diabetic neuropathies; Intermittent claudication
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 02 Aug 2002 Discontinued - Phase-III for Pulmonary hypertension in Canada (PO)
- 02 Aug 2002 Discontinued - Phase-III for Pulmonary hypertension in the US (PO)